PIK3CA Mutation Clinical Trials

7 clinical trials for PIK3CA Mutation across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) — RECRUITING · PHASE2
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — RECRUITING · PHASE3
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors — RECRUITING · PHASE1
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer — RECRUITING · PHASE1
• Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations — TERMINATED · PHASE1
• First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors — COMPLETED · PHASE1
• Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma — WITHDRAWN · PHASE1

Refine this search